drugset
drugset / Trial / NCT01954589

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

NCT01954589 ↗

Phase 1 Completed 56 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverTriple-blindOther

Summary

A study of ACT-462206 to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamic of ascending single doses of ACT-462206, a novel dual orexin receptor antagonist in healthy male subjects.

Timeline

Start
2011-11
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ACT-462206 Small molecule 5 mg Oral
Subject ACT-462206 Small molecule 25 mg Oral
Subject ACT-462206 Small molecule 100 mg Oral
Subject ACT-462206 Small molecule 200 mg Oral
Subject ACT-462206 Small molecule 400 mg Oral
Subject ACT-462206 Small molecule 1000 mg Oral
Subject ACT-462206 Small molecule 1500 mg Oral
Subject almorexant Small molecule 400 mg Oral

Indications

No indication recorded.